Core One Labs Conducts 8 To 1 Share Consolidation In Pursuit Of Nasdaq Listing
Core One Labs (CSE: COOL) early this morning reiterated that it is the latest junior Canadian equity with US big
Read more
Psychedelics
Numinus Wellness’ Study On MDMA-Assisted Therapy For PTSD Gets Health Canada Nod
Numinus Wellness Inc. (TSXV: NUMI) announced today that it has secured approval from Health Canada to conduct its feasibility study
Read more
Psyched Wellness Completes 14 Day Oral Toxicity Preclinical Study For Proprietary Extract
Psyched Wellness (CSE: PSYC) this morning announced the results of its initial 14-day oral toxicity preclinical study. The study was
Read more
PharmaTher: Maxim Initiates Coverage With US$1.50 Price Target
PharmaTher Holdings (CSE: PHRM) had its first initiation report that came out on June 28th. Maxim Group initiated coverage on
Read more
Psyched Wellness Commences 90-Day Toxicity Study Of AME-1
Psyched Wellness (CSE: PSYC) continues to progress on its preclinical studies for its novel mushroom extract formulation. The company this
Read more
Compass Pathways Closes Enrollment For Phase IIb Psilocybin Clinical Trial
Compass Pathways (NASDAQ: CMPS) this morning provided a brief update to the market on the latest status of its ongoing
Read more
SpeakEasy Cannabis Looks To Enter Psychedelics Space Via Acquisition
SpeakEasy Cannabis Club (CSE: EASY) is evidently looking to get into the psychedelics space now that investor sentiment has somewhat
Read more
Bright Minds: Focusing On Second Generation Psychedelic Compounds – The Daily Dive
Starting off this week on the Daily Dive is that of Dr Gideon Shapiro, whom is VP of Discovery at
Read more
Atai Life Sciences Increases IPO To $225 Million
Atai Life Sciences (NASDAQ: ATAI) late last night announced the pricing of its upsized initial public offering. The clinical-stage biotech
Read more
Revive Therapeutics Partners With University of Health Sciences Antigua To Further Psychedelics Research
Revive Therapeutics (CSE: RVV) this morning announced that it has entered into a collaboration to further advance its psychedelic-assisted therapies.
Read more